Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare la sicurezza e la tollerabilità di Dapirolizumab Pegol nei partecipanti allo studio con lupus eritematoso sistemico

9 novembre 2026 aggiornato da: UCB Biopharma SRL

Uno studio di estensione multicentrico in aperto per valutare la sicurezza e la tollerabilità a lungo termine del trattamento con Dapirolizumab Pegol nei partecipanti allo studio con lupus eritematoso sistemico

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Panoramica dello studio

Stato

Iscrizione su invito

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

760

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Buenos Aires, Argentina
        • Sl0046 60002
      • Mendoza, Argentina
        • Sl0046 60029
      • Quilmes, Argentina
        • Sl0046 60003
      • Quilmes, Argentina
        • Sl0046 60022
      • San Juan, Argentina
        • Sl0046 60011
      • San Miguel de Tucumán, Argentina
        • Sl0046 60014
      • Brussels, Belgio
        • Sl0046 40123
      • Plovdiv, Bulgaria
        • Sl0046 40189
      • Sofia, Bulgaria
        • Sl0046 40380
      • Calgary, Canada
        • Sl0046 50374
      • Edmonton AB, Canada
        • Sl0046 50337
      • Rimouski, Canada
        • Sl0046 50259
      • Toronto, Canada
        • Sl0046 50045
      • Prague, Cechia
        • Sl0046 40066
      • Santiago, Chile
        • Sl0046 60018
      • Santiago, Chile
        • Sl0046 60015
      • Beijing, Cina
        • Sl0046 20128
      • Changchun, Cina
        • Sl0046 20291
      • Guangzhou, Cina
        • Sl0046 20019
      • Guilin, Cina
        • Sl0046 20290
      • Shanghai, Cina
        • Sl0046 20020
      • Shantou, Cina
        • Sl0046 20346
      • Suzhou, Cina
        • Sl0046 20204
      • Tianjin, Cina
        • Sl0046 20136
      • Wenzhou, Cina
        • Sl0046 20025
      • Wuhan, Cina
        • Sl0046 20180
      • Yangzhou, Cina
        • Sl0046 20273
      • Zhengzhou, Cina
        • Sl0046 20132
      • Barranquilla, Colombia
        • Sl0046 60013
      • Barranquilla, Colombia
        • Sl0046 60019
      • Bogotá, Colombia
        • Sl0046 60006
      • Bogotá, Colombia
        • Sl0046 60027
      • Bucaramanga, Colombia
        • Sl0046 60016
      • Chía, Colombia
        • Sl0046 60007
      • Montería, Colombia
        • Sl0046 60031
      • Incheon, Corea del Sud
        • Sl0046 20108
      • Seoul, Corea del Sud
        • Sl0046 20104
      • Davao City, Filippine
        • Sl0046 20182
      • Makati, Filippine
        • Sl0046 20181
      • Cologne, Germania
        • Sl0046 40386
      • Freiburg im Breisgau, Germania
        • Sl0046 40072
      • Herne, Germania
        • Sl0046 40027
      • Leipzig, Germania
        • Sl0046 40078
      • Tübingen, Germania
        • Sl0046 40402
      • Vogelsang-gommern, Germania
        • Sl0046 40715
      • Nagoya, Giappone
        • Sl0046 20287
      • Athens, Grecia
        • Sl0046 40378
      • Athens, Grecia
        • Sl0046 40501
      • Crete, Grecia
        • Sl0046 40377
      • Larissa, Grecia
        • Sl0046 40507
      • Catania, Italia
        • Sl0046 40084
      • Milan, Italia
        • Sl0046 40448
      • Chihuahua City, Messico
        • Sl0046 50317
      • Cuernavaca, Messico
        • Sl0046 50250
      • Guadalajara, Messico
        • Sl0046 50249
      • León, Messico
        • Sl0046 50271
      • Monterrey, Messico
        • Sl0046 50251
      • Mérida, Messico
        • Sl0046 50252
      • Lima, Perù
        • Sl0046 60023
      • Lima, Perù
        • Sl0046 60009
      • Bialystok, Polonia
        • Sl0046 40482
      • Bydgoszcz, Polonia
        • Sl0046 40119
      • Katowice, Polonia
        • Sl0046 40398
      • Krakow, Polonia
        • Sl0046 40502
      • Lublin, Polonia
        • Sl0046 40151
      • Poznan, Polonia
        • Sl0046 40044
      • Poznan, Polonia
        • Sl0046 40090
      • Warsaw, Polonia
        • Sl0046 40097
      • Warsaw, Polonia
        • Sl0046 40098
      • Wroclaw, Polonia
        • Sl0046 40397
      • Wroclaw, Polonia
        • Sl0046 40481
      • Caguas, Porto Rico
        • Sl0046 50671
      • Galati, Romania
        • Sl0046 40382
      • Belgrade, Serbia
        • Sl0046 40393
      • Belgrade, Serbia
        • Sl0046 40461
      • Belgrade, Serbia
        • Sl0046 40730
      • Novi Sad, Serbia
        • Sl0046 40392
      • Barcelona, Spagna
        • Sl0046 40160
      • Málaga, Spagna
        • Sl0046 40341
      • Sabadell, Spagna
        • Sl0046 40101
      • Vigo, Spagna
        • Sl0046 40099
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • Sl0046 50140
    • Arizona
      • Avondale, Arizona, Stati Uniti, 85392
        • Sl0046 50058
      • Glendale, Arizona, Stati Uniti, 85306
        • Sl0046 50662
      • Phoenix, Arizona, Stati Uniti, 85032
        • Sl0046 50052
      • Tucson, Arizona, Stati Uniti, 85704
        • Sl0046 50328
    • California
      • Beverly Hills, California, Stati Uniti, 90210
        • Sl0046 50383
      • La Palma, California, Stati Uniti, 90623-1730
        • Sl0046 50275
      • San Leandro, California, Stati Uniti, 94578
        • Sl0046 50316
    • Colorado
      • Denver, Colorado, Stati Uniti, 80230
        • Sl0046 50339
    • Florida
      • Brandon, Florida, Stati Uniti, 33511
        • Sl0046 50239
      • Gainesville, Florida, Stati Uniti, 32610
        • Sl0046 50362
      • Miami, Florida, Stati Uniti, 33172
        • Sl0046 50681
      • Ormond Beach, Florida, Stati Uniti, 32174
        • Sl0046 50059
      • Plantation, Florida, Stati Uniti, 33324
        • Sl0046 50324
      • Tampa, Florida, Stati Uniti, 33606
        • Sl0046 50329
      • Tampa, Florida, Stati Uniti, 33618
        • Sl0046 50698
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30303
        • Sl0046 50368
    • Idaho
      • Idaho Falls, Idaho, Stati Uniti, 83404
        • Sl0046 50240
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60616
        • Sl0046 50699
    • Kentucky
      • Hopkinsville, Kentucky, Stati Uniti, 42240-1746
        • Sl0046 50474
    • Louisiana
      • Lake Charles, Louisiana, Stati Uniti, 70605
        • Sl0046 50285
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Sl0046 50660
    • Maryland
      • Hagerstown, Maryland, Stati Uniti, 21740
        • Sl0046 50015
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48201
        • Sl0046 50219
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Sl0046 50273
    • New York
      • Canton, New York, Stati Uniti, 13617
        • Sl0046 50366
      • Manhasset, New York, Stati Uniti, 11030
        • Sl0046 50264
      • New York, New York, Stati Uniti, 10032
        • Sl0046 50334
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28211
        • Sl0046 50238
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Sl0046 50147
    • Tennessee
      • Jackson, Tennessee, Stati Uniti, 38305
        • Sl0046 50001
    • Texas
      • Bellaire, Texas, Stati Uniti, 77401
        • Sl0046 50738
      • Colleyville, Texas, Stati Uniti, 76034
        • Sl0046 50418
    • West Virginia
      • Beckley, West Virginia, Stati Uniti, 25801
        • Sl0046 50050
      • Taichung, Taiwan
        • Sl0046 20113
      • Taichung, Taiwan
        • Sl0046 20142
      • Taipei, Taiwan
        • Sl0046 20095
      • Taiyuan, Taiwan
        • Sl0046 20082
      • Budapest, Ungheria
        • Sl0046 40412
      • Debrecen, Ungheria
        • Sl0046 40411
      • Szeged, Ungheria
        • Sl0046 40031
      • Székesfehérvár, Ungheria
        • Sl0046 40499

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

16 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment
  • The participant completed one of the parent studies within 4 weeks prior to entry to this study

Exclusion Criteria:

- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dapirolizumab pegol

Subjects will receive dapriolizumab pegol throughout the Treatment Period.

Subjects will receive dapirolizumab pegol at prespecified time-points.

Altri nomi:
  • CDP7657
  • DZP

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of treatment-emergent adverse events (TEAEs) during the study
Lasso di tempo: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of serious treatment-emergent adverse events during the study
Lasso di tempo: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:

  • Results in death
  • Is life-threatening
  • Requires in patient hospitalisation or prolongation of existing hospitalisation
  • Results in persistent disability/incapacity
  • Is a congenital anomaly or birth defect
  • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation
Lasso di tempo: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, and leading to permanent drug discontinuation whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24
Lasso di tempo: Week 24

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 24
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48
Lasso di tempo: Week 48

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 48
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104
Lasso di tempo: Week 104

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 104
Achievement of LLDAS at Week 48
Lasso di tempo: Week 48

Low lupus disease activity state (LLDAS) is defined as:

  • No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever)
  • No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
  • PGA ≤33 mm
  • Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day
  • Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Week 48
Achievement of LLDAS at Week 104
Lasso di tempo: Week 104

Low lupus disease activity state (LLDAS) is defined as:

  • No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever)
  • No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
  • PGA ≤33 mm
  • Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day
  • Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Week 104
Achievement of BICLA response at Week 48 (using the parent study baseline as the reference point)
Lasso di tempo: Week 48

A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled:

  1. British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale
Week 48
Achievement of BICLA response at Week 104 (using the parent study baseline as the reference point)
Lasso di tempo: Week 104

A study participant is considered to be a BICLA responder if all of the following is fulfilled:

  1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale
Week 104
Achievement of SRI-4 response at Week 48 (using the parent study baseline as the reference point)
Lasso di tempo: Week 48

The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met):

  • Reduction in SLEDAI-2K score of ≥4
  • No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
  • No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline
  • No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.
Week 48
Achievement of SRI-4 response at Week 104 (using the parent study baseline as the reference point)
Lasso di tempo: Week 104

The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met):

  • Reduction in SLEDAI-2K score of ≥4
  • No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
  • No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline
  • No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.
Week 104
Change from parent study Baseline in FATIGUE-PRO Total score at Week 48
Lasso di tempo: From Baseline to Week 48

The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.

From Baseline to Week 48
Change from parent study Baseline in FATIGUE-PRO Total score at Week 104
Lasso di tempo: From Baseline to Week 104

The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.

From Baseline to Week 104
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 48
Lasso di tempo: From Baseline to Week 48

The achievement of a reduction in glucocorticoid dose from >7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 48

From Baseline to Week 48
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 104
Lasso di tempo: From Baseline to Week 104

The achievement of a reduction in glucocorticoid dose from >7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 104

From Baseline to Week 104

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: UCB Cares, 001 844 599 2273 (UCB)

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 luglio 2021

Completamento primario (Stimato)

7 agosto 2030

Completamento dello studio (Stimato)

7 agosto 2030

Date di iscrizione allo studio

Primo inviato

14 luglio 2021

Primo inviato che soddisfa i criteri di controllo qualità

14 luglio 2021

Primo Inserito (Effettivo)

26 luglio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SL0046
  • 2019-003409-83 (Numero EudraCT)
  • U1111-1293-7098 (Altro identificatore: World Health Organization (WHO))
  • 2023-506368-14 (Identificatore di registro: EU Clinical Trials)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 2019 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Periodo di condivisione IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Criteri di accesso alla condivisione IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi